"We were hopeful to get a larger market share this year," Novavax CEO John Jacobs said in an interview, adding the company was averaging about 3% of the market weekly. If the company doesn't see the sales trend turn more positive in the current quarter ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.